Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Okogen Inc. maintains a patent portfolio within the Biotechnology & Pharmaceuticals technology area. The company currently faces 3 pending office actions, which are distributed among 3 distinct examiners. This distribution shows that each active matter is receiving an independent evaluation from a different individual at the patent office, rather than having prosecution concentrated under one person.
The workload is further spread across 3 distinct art units, suggesting that the company's technology covers several specialized areas within the Biotechnology & Pharmaceuticals field. SWIFT, CANDICE LEE is the busiest examiner for the portfolio, currently overseeing 1 busiest examiner pending office action. Because the 3 pending office actions are split across different examiners and art units, the company must manage a diverse set of prosecution requirements. For a practitioner, this means that strategies must be tailored to the specific norms of each art unit and the preferences of each examiner. The lack of concentration in the current data suggests a broad and varied approach to the company's intellectual property development.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| §103 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SWIFT, CANDICE LEE | 1 | 57.5% | +36.0% |
| FAN, LYNN Y | 1 | 47.3% | +49.5% |
| SIFFORD, JEFFREY MARK | 1 | 55.1% | +32.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17906631 | RIBONUCLEASES FOR TREATING VIRAL INFECTIONS | SIFFORD, JEFFREY MARK | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18547164 | PHARMACEUTICAL COMPOSITIONS COMPRISING RANPIRNASE | SWIFT, CANDICE LEE | — |
| 17996577 | TREATMENT OF VIRAL CONJUNCTIVITIS | FAN, LYNN Y | — |
| 17906631 | RIBONUCLEASES FOR TREATING VIRAL INFECTIONS | SIFFORD, JEFFREY MARK | — |
| Art Unit | Apps |
|---|---|
| 1657 | 1 |
| 1759 | 1 |
| 1671 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18547164 | PHARMACEUTICAL COMPOSITIONS COMPRISING RANPIRNASE | SWIFT, CANDICE LEE | 1657 | §102§103§112DPOther | Non-Final OA | — | Pending | Aug 21, 2023 |
| 17996577 | TREATMENT OF VIRAL CONJUNCTIVITIS | FAN, LYNN Y | 1759 | §103 | Final Rejection | — | Pending | Oct 19, 2022 |
| 17906631 | RIBONUCLEASES FOR TREATING VIRAL INFECTIONS | SIFFORD, JEFFREY MARK | 1671 | §101§103§112Other | Non-Final OA | — | Pending | Sep 19, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial